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ABSTRACT 
  
Introduction: Hypercholesterolemia is a condition characterized by very high levels of cholesterol in 
the blood. Inherited forms of hypercholesterolemia can also cause health problems related to the 
buildup of excess cholesterol in other tissues In this research are used the results of biochemical 
analyses and laboratory testing of cholesterol fromprivate health diagnostic laboratoryin east 
Macedonia of two years(2010-2011). The purpose of this research is to show the prevalence and the 
risk of appearance of possible hypercholesterolemia defined by gender and age.  
Results and discussion: According to the analyzed results, we have concluded that in the male 
population most of the patients with higher concentration of cholesterol are in the age group between 
40 and 60, but in the female population most cases of elevated higher concentration of cholesterol are 
in the age group over 60. It has been established a generation link i.e. elevated concentration of 
cholesterol appearing in two generations in one family. 
Conclusion: Hypercholesterolemia is a disease which is primary importance is to be detected and 
treated accordingly in its early stages with clinical laboratory methods and criteria, and molecular 
diagnostic methods for detection of the genetic reason for the appearance of this disease and 
appropriate treatment for patients and extension of their life span. 
 
Key words: Hypercholesterolemia, LDL-cholesterol, total cholesterol, FH, Cardiovascular disease, 
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INTRODUCTION 
Hypercholesterolemia is a condition 
characterized by very high levels of 
cholesterol in the blood. Inherited forms of 
hypercholesterolemia can also cause health 
problems related to the buildup of excess 
cholesterol in other tissues. 
[1] 
Familial 
Hypercholesterolemia (FH) represents a 
genetic disorder mostly induced by mutation 
of the gene for the receptor for low density 
lipoproteins (LDLR) and the gene for 
apolipoprotein B. 
[1-3] 
FH is inherited disease 
and as such is characterized by elevated 
quantity of total cholesterol and LDL- 
cholesterol, as a result of the presence of 
dysfunctional receptors for LDL-cholesterol 
or deficiency of receptors for LDL-
cholesterol in the liver, which will cleanse 
the LDL-cholesterol from the 
blood.Familial hypercholesterolemia (FH) is 
one of the frequent genetic disease that 
affects 1 in 500 individuals in human 
population. The research shows that about 
20 % of individuals with FH are diagnosed 
and only 7 % of them are adequately 
treated. 
[4,5,6]
 FH is caused by a mutation of 
the gene responsible like receptor for low-
density lipoprotein (LDLR) and 
apolipoprotein B (apoB). 
[7-10] 
FH is 
autosomal dominant disease characterized 
by elevated amounts of total cholesterol and 
LDL - cholesterol, due to the presence of 
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dysfunctional receptors for LDL - 
cholesterol or lack receptors for LDL- 
cholesterol in the liver. Patients with 
hypercholesterolemia have chronically high 
concentrations of total cholesterol and high 
levels of cholesterol LDL (10). Patients with 
FH are predisposed to premature 
atherosclerotic cardiovascular disease and 
xanthomas on the skin. Conventional 
diagnosis of this disease can be performed 
at any age with clinical and biochemical 
tests but the early diagnosis of this disease is 
very important because they confirm the 
family medical history and prevent the risks 
and consequences of FH. 
[10,11] 
FH is a 
genetic disease very often in heterozygotes 
with prevalence of approximately 1 in 500 
people in most Western countries, while 
very severe homozygous form of the disease 
occurring in approximately 1 in 1,000,000 
people. It is estimated that over 10 million 
people worldwide are affected by this 
disease, and about 200,000 die annually of 
premature coronary heart disease. 
[7, 12-16]
 
THE MAIN OF THE RESEARCH 
 To evaluate the riskof 
hypercholesterolemiain general 
population in east Macedonia, (aged 
more than 18 years) 
 To evaluate the prevalence of 
hypercholesterolemia on patients 
from east Macedonia 
 To identify which population (male 
or female) is most affected by the 
disease as hypercholesterolemia  
 To determining the age structure of 
hypercholesterolemia that usually 
manifest clinically  
 To explain the possible implications 
that occurs in hypercholesterolemia 
(respective to different age or 
gender) 
 
MATERIALS AND METHODS   
We used biochemical results - 
laboratory testing of private health 
diagnostic laboratory in east Macedonia, 
from January 2010 to December 2011 (two 
years), includes all social and gender 
structures, ranging from 12 years-to 90 
years old. Cholesterol tests are performed 
with biochemical analyzer Cobas C111 - 
Roche Diagnostics.Interpretation of the 
results of cholesterol are guided by the 
clinical interpretation of the results 
according to recommendations of the 
European Society of Atherosclerosis 
(European Atherosclerosis Society), which 
is as follows: 
 If the cholesterol is below 5.2 
mmol/L and triglyceride values 
below 2.3 mmol/L, than the patient 
has not lipid metabolic disorders 
 If the cholesterol values ranging 
from 5.2-7.8 mmol/L and HDL-
cholesterol if below 0.9 mmol/ l, 
than we can say that there are 
possible lipid metabolic disorder in 
this patient  
 If the values of cholesterol above 7.8 
mmol / L and triglyceride values 
above 2.3 mmol / L, we can confirm 
that the patient has lipid metabolic 
disorders 
 As a basic indicator of possible 
hypercholesterolemia patients will use 
cholesterol values that exceed the value of 
7.8 mmol/L. Patients who are the target of 
this research is divided into three age 
categories: 
Patients below 40 ages 
Patients with 40-60 ages  
Patients above 60 ages 
 
RESULTS 
From the time of January 2010 to 
December 2011, in the private diagnostic 
laboratory in east Macedonia are completed 
total 2376 laboratory analysis of patients 
where among other analyzes and measured 
the concentration of total cholesterol. 904 
patients (of total 2376) have a cholesterol 
concentration higher than 5.2 mmol/L. This 
results shows that 38.05 % of the total 
number of patients who came (2376) and 
made the analysis and measurement of the 
concentration of total cholesterol had 
cholesterol levels that exceed the limit of 
5.2 mmol/L. 
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Table 1. Display of total number of patients (males and females) with cholesterol higher the 5.2 mmol/L 
Patients with cholesterol concentration higher than 5.2 mmol/L N0 
Male 367 (40,6%) 
Female  537 (59,4%) 
Total 904 (100%) 
 
 
Fig.1. Graphical display of the proportional representation of 
elevated cholesterol among male and female patients. 
 
The total numbers of patients with 
elevated cholesterol are 904, the total 
number of patients who have cholesterol 
higher than 7.8 mmol/L is 92. 32 of them 
are male patients and 60 of them are female 
patient.  
 
 
Fig.2. Graphic display of the male patients with cholesterol 
higher than 7.8mmol/L grouped by age criteria. 
 
Table 2. Display of total number and the number of patients by gender, with cholesterol higher than 7.8 mmol/L. 
Total patients with cholesterol concentration higher than 7.8 mmol/L 92 100% 
Male 32 34.78% 
Female 60 65.22% 
 
Table 3. Display of male patients with cholesterol higher than 7.8 mmol/L by age. 
Male patients with cholesterol higher than7.8 mmol/L below 40 age  6 18.75% 
Male patients with cholesterol higher than7.8 mmol/L between 40-60 age 18 56.25% 
Male patients with cholesterol higher than7.8 mmol/L above 60 age. 8 25% 
Total male patients with cholesterol higher than7.8 mmol/L 32 100% 
 
Table 4. Display of female patients with cholesterol higher than 7.8 mmol/L by age. 
Female patients with cholesterol higher than7.8 mmol/L below 40 age 3 5% 
Female patients with cholesterol higher than7.8 mmol/L between 40-60 age 19 31.67% 
Female patients with cholesterol higher than 7.8 mmol/L above 60 age 38 63.33% 
Total female patients with cholesterol higher than7.8 mmol/L  60 100% 
 
 
Fig.3. Graphic display of the female patients with cholesterol 
higher than 7.8 mmol/L grouped by age criteria. 
 
In group of the males we registered a 
case of a patient born in 1960with the 
highest measured cholesterol (15.24 mmol 
/L). In this same patient are observed very 
high concentration of triglycerides (11.40 
mmol/L). Another case with a very high 
concentration of cholesterol is found in a 
patient born in 1972, with measured 14.47 
mmol/L cholesterol and triglycerides in 
concentration of 4.70 mmol/L. The 
youngest male patient with high cholesterol 
is observed in patients born in 1985 and it 
has the concentration of cholesterol 9.04 
mmol/L. It must be noted that in two cases 
(work for different families) are met by 
elevated concentrations of cholesterol in 
different generations. The first case is the 
aforementioned patient with the highest 
measured concentration of 15.24 mmol / L 
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born in 1960 and his son was born in 1988 
with the measured concentration of 
cholesterol in serum of 8.5 mmol / L. The 
second case is a female patient born in 1945 
with measured concentration of cholesterol 
by 9.04 mmol/L and her daughter born in 
1974 with the cholesterol concentration of 
9.84 mmol/L. 
 
Table 5. Diagnosis (Hypercholesterolemia is diagnosed if total cholesterol levels exceed the cut point) 
 Total cholesterol cutpoints (mmol/L) 
Age 
(years) 
First-degree relative with 
hypercholesterolemia 
Second-degree relative with 
hypercholesterolemia 
Third-degree relative with 
hypercholesterolemia 
General 
population 
<20 5.7 5.9 6.2 7.0 
20–29 6.2 6.5 6.7 7.5 
30–39 7.0 7.2 7.5 8.8 
≥40 7.5 7.8 8.0 9.3 
  
The risk of FH in the general 
population in east Macedonia is present, but 
it isn’t possible to fully display the real 
situation due to effects of the external 
factors. 
 Based on available information from 
the diary of the patients we conclude 
existence and risks of 
hypercholesterolemia based on a fact 
that 38.05 % of the patients had 
cholesterol levels that exceed the limit 
from 5.2 mmol / L. 
 The total number of laboratory tests 
made in private diagnostic laboratory 
in east Macedonia for the time of two 
years (2010-2011) is 2.376, revealed a 
total of 92 patients with a total 
cholesterol concentration higher than 
7.8 mmol/L. Expressed as a 
percentage this is 3.87 % 
 
DISCUSSION 
Hypercholesterolemia is caused by a 
combination of genetic and environmental 
factors, such as diet, smoking, intake of 
foods, stress. On the concentration of 
cholesterol and affecting factors such as 
gender, age, health status, certain diseases 
such as health problems related to heart, 
diabetes and proneness to fattening - 
obesity. The results of the study shows that 
the increased concentration of cholesterol is 
present in most females 59.4 %, than in 
men’s (this percentage is 40.6 %). 65.22 % 
of the female population have a cholesterol 
greater than 7.8 mmol/L, which is the 
possible diagnosis of FH and they are much 
more prevalent among men (that percentage 
is 34.78 %).  
 The results of the study that the male 
population between 40-60 years is the 
most threatened population with 
cholesterol higher than 7.8 mmol/L 
followed by the number of cases.  
 In the female population the most 
risks population is aged over 60 years. 
The hight level of cholesterol in the 
group between 40 to 60 years of 
men’s population is results by 
reducing the secretion of testosterone 
which has not the anabolic effect of 
androgen and testosterone, which 
contributes to an increase in the 
concentration of cholesterol.  
 Most patients with high levels of 
cholesterol, females are aged over 60, 
than from 40 to 60 years we have also 
a number of patients and have the 
lowest number of patients under 40 
years. This ratio could be explained by 
the effect of female hormones that 
speed up metabolism, intensifying the 
process of storing fat, increase HDL- 
cholesterol and lower LDL- 
cholesterol.  
 The FH clinical phenotype has been 
shown to be associated with increased 
coronary heart disease and premature death. 
Mutations in the low density lipoprotein 
receptor gene (LDLR) can result in the FH 
phenotype, and there is evidence that 
receptor-negative mutations result in a more 
severe phenotype than do receptor-defective 
mutations. 
[12] 
Although it is recognized that 
in heterozygous familial 
hypercholesterolemia, large extracranial 
carotid vessels are affected by 
atherosclerosis, 
[6,15,17,18]
 the risk of fatal 
stroke after treatment with cholesterol-
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lowering therapy remains uncertain. 
[15] 
Haemodynamically significant peripheral 
vascular disease appears to be more 
prevalent in FH patients than is generally 
assumed. 
[6]
 
 
CONCLUSION 
 Early diagnosis of 
hypercholesterolemia is very important for 
patients. Important in terms of treatment 
would be recommended in these patients 
and it would be prevented lethal outcome in 
these individuals because they have risks of 
coronary artery disease. The clinical 
diagnostic criteria for hypercholesterolemia 
suggests the need for genetic testing in cases 
where there are confrontational factors such 
as the level of cholesterol in the final 
ceilings, vague family history, mainly in 
patients where there is diagnostic dilemma. 
The main value of molecular diagnostics is 
the use in predicate testing for FH of family 
members. This is important for early 
detection of FH, in order to prevent cardio-
vascular diseases and insurance for family 
members about whether they have the 
disease or not. 
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